Abstract WP298: Intracisternal Bolus Administration of Stanniocalcin-2 Promotes Post-Stroke Recovery in a Translational Aged Rodent Model

Abstract

Stanniocalcin-2 (STC-2) is a glycoprotein implicated in multiple physiological pathways, including calcium and phosphate homeostasis, cell proliferation, and anti-inflammatory responses. The molecular mechanisms by which STC-2 functions in the brain and its specific roles in various neurological processes are not well-defined. We have previously shown that intraventricular administration of STC-2 post-stroke increases endogenous stem cell production and improves functional recovery in an adult rodent model of distal middle cerebral artery occlusion (dMCAO). To further investigate the translatability and preclinical efficacy of STC-2 as a protein therapeutic, we intracisternally administered recombinant STC-2 one week post-dMCAO in aged rats (18-24 months) and comprehensively assessed recovery over a 6 week period via sensorimotor, locomotor, and cognitive tasks. Our results indicate that just two bolus intracisternal injections of STC-2 improved stroke recovery in a battery of behavioral assessments in comparison to a control group (n=9 per group, unpaired t-tests with Welch's correction, see Figure 1A-D). Improved sensorimotor recovery (as assessed by vibrissae-forepaw and hind-rearing tests), locomotor recovery (as assessed by an open field test), and cognitive recovery (as assessed by a novel object recognition test) were observed. Further research is required to delve into the underlying molecular mechanisms responsible. Nevertheless, we are optimistic about the substantial translational prospects of this study. Our findings have the potential to pave the way for a novel protein therapeutic for the treatment of stroke deficits.